AWM Investment Company Inc. bought a new position in shares of Alpha Cognition Inc. (NASDAQ:ACOG - Free Report) during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 1,672,168 shares of the company's stock, valued at approximately $12,073,000. AWM Investment Company Inc. owned approximately 7.68% of Alpha Cognition at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also modified their holdings of ACOG. Aristides Capital LLC boosted its stake in shares of Alpha Cognition by 1.4% in the 1st quarter. Aristides Capital LLC now owns 218,510 shares of the company's stock valued at $1,200,000 after purchasing an additional 3,052 shares during the last quarter. Geode Capital Management LLC bought a new position in Alpha Cognition in the second quarter valued at approximately $112,000. Massar Capital Management LP bought a new position in Alpha Cognition in the second quarter valued at approximately $116,000. Two Sigma Investments LP acquired a new stake in Alpha Cognition during the 3rd quarter worth $148,000. Finally, Boothbay Fund Management LLC grew its holdings in Alpha Cognition by 10.8% during the 3rd quarter. Boothbay Fund Management LLC now owns 291,868 shares of the company's stock worth $1,900,000 after acquiring an additional 28,392 shares during the period.
Wall Street Analysts Forecast Growth
ACOG has been the subject of a number of recent analyst reports. HC Wainwright upped their price objective on Alpha Cognition from $18.00 to $20.00 and gave the company a "buy" rating in a report on Monday, August 17th. Raymond James Financial began coverage on shares of Alpha Cognition in a research report on Friday, July 10th. They issued an "outperform" rating and a $20.00 price target on the stock. Craig Hallum reissued a "buy" rating and set a $17.00 price objective on shares of Alpha Cognition in a research note on Friday, August 14th. Maxim Group initiated coverage on shares of Alpha Cognition in a report on Friday, May 29th. They set a "buy" rating and a $12.00 price objective for the company. Finally, B. Riley Financial started coverage on shares of Alpha Cognition in a research note on Thursday, August 20th. They issued a "buy" rating and a $21.00 target price for the company. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and an average target price of $18.00.
Read Our Latest Report on Alpha Cognition
Alpha Cognition Stock Performance
ACOG opened at $9.75 on Wednesday. Alpha Cognition Inc. has a 52-week low of $4.50 and a 52-week high of $10.14. The firm has a market capitalization of $212.35 million, a PE ratio of -8.86 and a beta of 2.31. The business's 50-day simple moving average is $8.20 and its 200 day simple moving average is $6.73.
Alpha Cognition (NASDAQ:ACOG - Get Free Report) last released its quarterly earnings data on Thursday, August 13th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.01). The firm had revenue of $6.00 million for the quarter, compared to analyst estimates of $4.38 million. Alpha Cognition had a negative return on equity of 54.60% and a negative net margin of 153.61%. On average, research analysts forecast that Alpha Cognition Inc. will post -1.38 earnings per share for the current year.
Insider Buying and Selling at Alpha Cognition
In other news, Director Robert James Wills bought 10,000 shares of the company's stock in a transaction dated Friday, August 21st. The stock was bought at an average price of $9.62 per share, with a total value of $96,200.00. Following the completion of the acquisition, the director owned 32,241 shares of the company's stock, valued at $310,158.42. This represents a 44.96% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Company insiders own 8.60% of the company's stock.
Alpha Cognition Profile
(
Free Report)
Alpha Cognition, Inc is a clinical stage biopharmaceutical company that develops treatments for underserved neurodegenerative diseases such as Alzheimer's Dementia and Amyotrophic Lateral Sclerosis. The company was founded in 2000 and is headquartered in Vancouver, Canada.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Before you consider Alpha Cognition, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Alpha Cognition wasn't on the list.
While Alpha Cognition currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
